Date  |
|
| Jun 9, 2021 |
9 Meters Biopharma, Inc. to Present at 2021 BIO Digital |
| Jun 14, 2021 |
9 Meters Announces Initiation of Phase 2 VIBRANT Study of Vurolenatide for Short Bowel Syndrome |
| Jun 28, 2021 |
9 Meters Added to Russell 2000(R) and 3000(R) Indexes |
| Jul 8, 2021 |
9 Meters Biopharma, Inc. To Present at the William Blair Biotech Focus Conference |
| Jul 19, 2021 |
9 Meters Biopharma, Inc. Announces the Acquisition of Humanized Anti-GIP Monoclonal Antibody from Lobesity |
| Aug 5, 2021 |
9 Meters Biopharma, Inc. to participate in BMO Capital Markets' "Biopharma Spotlight Series: Innovation in GI" |
| Aug 12, 2021 |
9 Meters Biopharma Provides Business Update and Reports Financial Results for the Second Quarter 2021 |
| Aug 16, 2021 |
9 Meters Biopharma, Inc. Announces Collaboration with EBRIS Foundation for Planned Phase 2 Study of Larazotide for the Treatment of Multisystem Inflammatory Syndrome in Children (MIS-C) Resulting from COVID-19 |
| Sep 1, 2021 |
9 Meters Biopharma, Inc. to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021 |
| Sep 8, 2021 |
9 Meters Biopharma, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference |